Corvus Pharmaceuticals (CRVS) Operating Leases (2022 - 2025)
Historic Operating Leases for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Q3 2025 value amounting to $632000.0.
- Corvus Pharmaceuticals' Operating Leases rose 7853.11% to $632000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $632000.0, marking a year-over-year increase of 7853.11%. This contributed to the annual value of $937000.0 for FY2024, which is 3180.49% down from last year.
- Per Corvus Pharmaceuticals' latest filing, its Operating Leases stood at $632000.0 for Q3 2025, which was up 7853.11% from $728000.0 recorded in Q2 2025.
- Corvus Pharmaceuticals' 5-year Operating Leases high stood at $2.3 million for Q1 2022, and its period low was $354000.0 during Q3 2023.
- In the last 4 years, Corvus Pharmaceuticals' Operating Leases had a median value of $937000.0 in 2024 and averaged $1.1 million.
- As far as peak fluctuations go, Corvus Pharmaceuticals' Operating Leases plummeted by 7904.09% in 2023, and later skyrocketed by 7853.11% in 2025.
- Corvus Pharmaceuticals' Operating Leases (Quarter) stood at $1.4 million in 2022, then increased by 0.07% to $1.4 million in 2023, then plummeted by 31.8% to $937000.0 in 2024, then tumbled by 32.55% to $632000.0 in 2025.
- Its Operating Leases was $632000.0 in Q3 2025, compared to $728000.0 in Q2 2025 and $834000.0 in Q1 2025.